Mean efficacy variables at baseline and the mean change after 24 weeks with the 95% confidence interval for the difference in change between the treatment groups
| Variable | Placebo (n = 15) | Leflunomide (n = 30) | 95% CI* | p Value | ||
|---|---|---|---|---|---|---|
| Baseline | Mean change | Baseline | Mean change | |||
| *95% confidence interval for difference of mean change between placebo and leflunomide. | ||||||
| †General wellbeing of the patient according to physician. | ||||||
| BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASG, Bath ankylosing spondylitis global score; BASMI, Bath ankylosing spondylitis metrology index; ESR, erythrocyte sedimentation rate; SJC, swollen joint count. | ||||||
| BASG last week (0–10) | 5.8 | −0.6 | 6.9 | −1.3 | (−0.9 to 2.4) | 0.32 |
| BASG last six months | 6.7 | −1.5 | 7.4 | −0.7 | (−2.2 to 0.6) | 0.26 |
| Pain (0–10) | 6.2 | −0.5 | 6.8 | −1.4 | (−0.9 to 2.8) | 0.28 |
| BASFI (0–10) | 5.4 | −0.4 | 5.2 | 0.0 | (−1.3 to 0.5) | 0.35 |
| BASDAI (0–10) | 5.9 | −0.3 | 6.4 | −1.1 | (−0.5 to 2.0) | 0.20 |
| BASMI (0–10) | 3.3 | 0.3 | 4.2 | 0.0 | (−0.1 to 0.8) | 0.10 |
| SJC (0–44) | 0.4 | −0.2 | 0.1 | 0.2 | (−0.9 to 0.1) | 0.09 |
| Global physician (0–10)† | 5.1 | −0.7 | 5.5 | −0.5 | (−1.1 to 0.8) | 0.70 |
| ESR (mm/h) | 18.1 | −1.9 | 22.1 | 8.4 | (−17.8 to −2.9) | 0.002 |
| C reactive protein (mg/l) | 21.4 | −6.1 | 27.0 | 6.5 | (−30.9 to 5.8) | 0.09 |